Claims

1. Use of the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling in a human patient, wherein the disease is heart failure with preserved ejection fraction (HF-PEF), wherein the NEP inhibitor pro-drug is administered together, concomitantly or sequentially with the Angiotensin Receptor Blocker valsartan or a pharmaceutically acceptable salt thereof.

2. The use according to claim 1, wherein the use is for the treatment of patients suffering from heart failure with preserved ejection fraction (HF-PEF) with no history of atrial fibrillation.

3. The use according to claim 1 or 2, wherein the use is for improvement, stabilization or delayed worsening in NYHA classification of patients suffering from heart failure with preserved ejection fraction (HF-PEF).

4. The use according to claim 1, wherein the NEP inhibitor pro-drug and the Angiotensin Receptor Blocker are administered in a 1:1 molar ratio.

5. The use according to claim 4, wherein the NEP inhibitor pro-drug and the Angiotensin Receptor Blocker in a 1:1 molar ratio are delivered by administration of LCZ696 as trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3'-methyl-2'-(pentanoyl{2”-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate]hemipentahydrate.

6. The use according to claim 5, wherein LCZ696 is administered twice daily at a dose of 50 mg, 100 mg, 200 mg or 400 mg.